- Soros: More Money Needed For U.S. Bailout
- HP Earnings: How Much Will "Hurt" From Economy?
- Obama Warns On Economy: Works On Stimulus Plan
- Citigroup's Ills May Signal Market Isn't Near Bottom
- US Inflation Bonds Hit by Deflation, May Recover
- Pros Say: Market Will Drop 5-10% — Ford Will Boom
- Bonds Drop on Profit-Taking, Geithner Move
- Jack Welch on Detroit: Let Them Go Bankrupt
- Bank Shareholders Face 'the Unthinkable': El-Erian
- Out with Cox, in with Uptick Rule
- Pops & Drops: Hewlett-Packard, JP Morgan & Air Wagoner
- Mad Money Green Week: Owens Corning
- Fast & Furious: It's All About Soup
- Web Extra: The Trade on Walmart and RIMM
- Chartology: Grossly Oversold and Favoring the Upside
- The "Armageddon" Gameplan
- What's Next for Citigroup?
- What to Expect From a Geithner-led Treasury
Giving everyone who's admitted to a hospital a quick test for the so-called "Superbug" doesn't significantly cut the number of infections and isn't cost-effective.
That's the conclusion of the biggest study yet that's just been published in the Journal of the American Medical Association. The journal also says in an editorial that hospitals can control the potentially fatal staph infections by using basic sanitary measures rather than "expensive" tests.
Researchers looked at nearly 22-thousand patients at a Swiss hospital who either got screened for the bacterial infection commonly known as MRSA or who used standard infection controls like hand gel. And they report that the universal testing did not reduce the incidence of MRSA infections.
Cepheid [CPHD
Loading...
()
] and Becton Dickinson [BDX
Loading...
()
] make MRSA tests which can give results much faster than the one used in the study and a few other companies are working on next-generation screening systems.
Cepheid CEO John Bishop told CNBC, "To say that it's (the MRSA test) not effective is an overstatement." Mr. Bishop said that MRSA is much less prevalent in Switzerland than in the U.S., so he argues it is much more difficult to show a reduction in infection rates in Switzerland than it is here.
In an email, Becton says this is just one "data point" and that many other studies have shown that testing for MRSA saves lives and money.





